<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:30:40Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9870218" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9870218</identifier>
        <datestamp>2023-01-24</datestamp>
        <setSpec>jco</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Clin Oncol</journal-id>
              <journal-id journal-id-type="hwp">jco</journal-id>
              <journal-id journal-id-type="publisher-id">JCO</journal-id>
              <journal-title-group>
                <journal-title>Journal of Clinical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0732-183X</issn>
              <issn pub-type="epub">1527-7755</issn>
              <publisher>
                <publisher-name>Wolters Kluwer Health</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9870218</article-id>
              <article-id pub-id-type="pmcid">PMC9870218</article-id>
              <article-id pub-id-type="pmc-uid">9870218</article-id>
              <article-id pub-id-type="pmid">36240478</article-id>
              <article-id pub-id-type="pmid">36240478</article-id>
              <article-id pub-id-type="publisher-id">JCO.21.02303</article-id>
              <article-id pub-id-type="doi">10.1200/JCO.21.02303</article-id>
              <article-id pub-id-type="art-access-id">00024</article-id>
              <article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>ORIGINAL REPORTS</subject>
                  <subj-group>
                    <subject>Genitourinary Cancer</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <italic toggle="yes">FGFR1</italic>/<italic toggle="yes">3</italic> mRNA Expression</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3938-2627</contrib-id>
                  <name>
                    <surname>Sternberg</surname>
                    <given-names>Cora N.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="con15" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6165-5797</contrib-id>
                  <name>
                    <surname>Petrylak</surname>
                    <given-names>Daniel P.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="con18" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2328-3421</contrib-id>
                  <name>
                    <surname>Bellmunt</surname>
                    <given-names>Joaquim</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="con11" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nishiyama</surname>
                    <given-names>Hiroyuki</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="con3" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3007-2756</contrib-id>
                  <name>
                    <surname>Necchi</surname>
                    <given-names>Andrea</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="con13" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0217-5261</contrib-id>
                  <name>
                    <surname>Gurney</surname>
                    <given-names>Howard</given-names>
                  </name>
                  <degrees>MBBS</degrees>
                  <xref rid="aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                  <xref rid="con8" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9420-7162</contrib-id>
                  <name>
                    <surname>Lee</surname>
                    <given-names>Jae-Lyun</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                  <xref rid="con1" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4407-7881</contrib-id>
                  <name>
                    <surname>van der Heijden</surname>
                    <given-names>Michiel S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <xref rid="con5" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rosenbaum</surname>
                    <given-names>Eli</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                  <xref rid="con16" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5243-1548</contrib-id>
                  <name>
                    <surname>Penel</surname>
                    <given-names>Nicolas</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff11" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                  <xref rid="con19" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pang</surname>
                    <given-names>See-Tong</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff12" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4626-9369</contrib-id>
                  <name>
                    <surname>Li</surname>
                    <given-names>Jian-Ri</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5571-2847</contrib-id>
                  <name>
                    <surname>García del Muro</surname>
                    <given-names>Xavier</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff14" ref-type="aff">
                    <sup>14</sup>
                  </xref>
                  <xref rid="con14" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7004-9895</contrib-id>
                  <name>
                    <surname>Joly</surname>
                    <given-names>Florence</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff15" ref-type="aff">
                    <sup>15</sup>
                  </xref>
                  <xref rid="con9" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pápai</surname>
                    <given-names>Zsuzsanna</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff16" ref-type="aff">
                    <sup>16</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bao</surname>
                    <given-names>Weichao</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff17" ref-type="aff">
                    <sup>17</sup>
                  </xref>
                  <xref rid="con6" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ellinghaus</surname>
                    <given-names>Peter</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff18" ref-type="aff">
                    <sup>18</sup>
                  </xref>
                  <xref rid="con17" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lu</surname>
                    <given-names>Chengxing</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff17" ref-type="aff">
                    <sup>17</sup>
                  </xref>
                  <xref rid="con20" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sierecki</surname>
                    <given-names>Mitchell</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff17" ref-type="aff">
                    <sup>17</sup>
                  </xref>
                  <xref rid="con12" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Coppieters</surname>
                    <given-names>Sabine</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff19" ref-type="aff">
                    <sup>19</sup>
                  </xref>
                  <xref rid="con4" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nakajima</surname>
                    <given-names>Keiko</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff17" ref-type="aff">
                    <sup>17</sup>
                  </xref>
                  <xref rid="con10" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2976-0295</contrib-id>
                  <name>
                    <surname>Ishida</surname>
                    <given-names>Tatiane Cristine</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff17" ref-type="aff">
                    <sup>17</sup>
                  </xref>
                  <xref rid="con2" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1411-0417</contrib-id>
                  <name>
                    <surname>Quinn</surname>
                    <given-names>David I.</given-names>
                  </name>
                  <degrees>MBBS, PhD</degrees>
                  <xref rid="aff20" ref-type="aff">
                    <sup>20</sup>
                  </xref>
                  <xref rid="cor1" ref-type="corresp"/>
                  <xref rid="con7" ref-type="fn"/>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>Englander Institute for Precision Medicine, Weill Cornell Medicine, Sandra and Edward Meyer Cancer Center, New York, NY</aff>
                <aff id="aff2"><label><sup>2</sup></label>Yale Cancer Center, New Haven, CT</aff>
                <aff id="aff3"><label><sup>3</sup></label>Beth Israel Deaconess Medical Center and PSMAR-IMIM Lab, Boston, MA</aff>
                <aff id="aff4"><label><sup>4</sup></label>Harvard Medical School, Boston, MA</aff>
                <aff id="aff5"><label><sup>5</sup></label>Department of Urology, University of Tsukuba, Tsukuba, Japan</aff>
                <aff id="aff6"><label><sup>6</sup></label>Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy</aff>
                <aff id="aff7"><label><sup>7</sup></label>Clinical Trials Unit FMHS, Macquarie University, Sydney, New South Wales, Australia</aff>
                <aff id="aff8"><label><sup>8</sup></label>University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea</aff>
                <aff id="aff9"><label><sup>9</sup></label>Medical Oncology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands</aff>
                <aff id="aff10"><label><sup>10</sup></label>Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel</aff>
                <aff id="aff11"><label><sup>11</sup></label>Lille University and Department of Medical Oncology, Centre Oscar Lambret, Lille, France</aff>
                <aff id="aff12"><label><sup>12</sup></label>Division of Urology, Department of Surgery, Linkou Chang Gung Memorial Hospital, Linkou, Taiwan</aff>
                <aff id="aff13"><label><sup>13</sup></label>Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan</aff>
                <aff id="aff14"><label><sup>14</sup></label>Department of Medical Oncology, University of Barcelona, Idibell Institute of Research, Institut Català d’Oncologia Hospitalet, Barcelona, Spain</aff>
                <aff id="aff15"><label><sup>15</sup></label>Clinical Research Department, Centre François Baclesse, Caen, France</aff>
                <aff id="aff16"><label><sup>16</sup></label>Oncology Department, Medical Centre, Hungarian Defence Forces, Budapest, Hungary</aff>
                <aff id="aff17"><label><sup>17</sup></label>Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ</aff>
                <aff id="aff18"><label><sup>18</sup></label>Bayer AG, Wuppertal, Germany</aff>
                <aff id="aff19"><label><sup>19</sup></label>Bayer AG, Diegem, Belgium</aff>
                <aff id="aff20"><label><sup>20</sup></label>Division of Oncology, Department of Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, CA</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">David I. Quinn, MBBS, PhD, Division of Oncology, Department of Medicine, USC Norris Comprehensive Cancer Center, 1441 Eastlake Ave, Ste 3440, Los Angeles, CA 90033; e-mail: <email>diquinn@usc.edu</email>.</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>20</day>
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>14</day>
                <month>10</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>14</day>
                <month>10</month>
                <year>2022</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>41</volume>
              <issue>3</issue>
              <fpage>629</fpage>
              <lpage>639</lpage>
              <history>
                <date date-type="received">
                  <day>27</day>
                  <month>9</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>21</day>
                  <month>3</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>4</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2022 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri xlink:href="jco-41-629.pdf"/>
              <related-object source-id-type="registry-name" document-id="NCT03410693" document-id-type="clinical-trial-number" source-type="clinical-trials-registry" source-id="ClinicalTrials.gov" id="d64e426"/>
              <abstract>
                <title>PURPOSE</title>
                <p>Rogaratinib, an oral pan-fibroblast growth factor receptor (FGFR1-4) inhibitor, showed promising phase I efficacy and safety in patients with advanced urothelial carcinoma (UC) with <italic toggle="yes">FGFR1-3</italic> mRNA overexpression. We assessed rogaratinib efficacy and safety versus chemotherapy in patients with <italic toggle="yes">FGFR</italic> mRNA-positive advanced/metastatic UC previously treated with platinum chemotherapy.</p>
                <sec>
                  <title>METHODS</title>
                  <p>FORT-1 (ClinicalTrials.gov identifier: <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT03410693" ext-link-type="uri">NCT03410693</ext-link>) was a phase II/III, randomized, open-label trial. Patients with <italic toggle="yes">FGFR1</italic>/<italic toggle="yes">3</italic> mRNA-positive locally advanced or metastatic UC with ≥ 1 prior platinum-containing regimen were randomly assigned (1:1) to rogaratinib (800 mg orally twice daily, 3-week cycles; n = 87) or chemotherapy (docetaxel 75 mg/m<sup>2</sup>, paclitaxel 175 mg/m<sup>2</sup>, or vinflunine 320 mg/m<sup>2</sup> intravenously once every 3 weeks; n = 88). The primary end point was overall survival, with objective response rate (ORR) analysis planned following phase II accrual. Because of comparable efficacy between treatments, enrollment was stopped before progression to phase III; a full interim analysis of phase II was completed.</p>
                </sec>
                <sec>
                  <title>RESULTS</title>
                  <p>ORRs were 20.7% (rogaratinib, 18/87; 95% CI, 12.7 to 30.7) and 19.3% (chemotherapy, 17/88; 95% CI, 11.7 to 29.1). Median overall survival was 8.3 months (95% CI, 6.5 to not estimable) and 9.8 months (95% CI, 6.8 to not estimable; hazard ratio, 1.11; 95% CI, 0.71 to 1.72; <italic toggle="yes">P</italic> = .67). Grade 3/4 events occurred in 37 (43.0%)/4 (4.7%) patients and 32 (39.0%)/15 (18.3%), respectively. No rogaratinib-related deaths occurred. Exploratory analysis of patients with <italic toggle="yes">FGFR3</italic> DNA alterations showed ORRs of 52.4% (11/21; 95% CI, 29.8 to 74.3) for rogaratinib and 26.7% (4/15; 95% CI, 7.8 to 55.1) for chemotherapy.</p>
                </sec>
                <sec>
                  <title>CONCLUSION</title>
                  <p>To our knowledge, these are the first data to compare FGFR-directed therapy with chemotherapy in patients with <italic toggle="yes">FGFR</italic>-altered UC, showing comparable efficacy and manageable safety. Exploratory testing suggested <italic toggle="yes">FGFR3</italic> DNA alterations in association with <italic toggle="yes">FGFR1</italic>/<italic toggle="yes">3</italic> mRNA overexpression may be better predictors of rogaratinib response.</p>
                </sec>
              </abstract>
              <counts>
                <fig-count count="1"/>
                <table-count count="5"/>
                <equation-count count="0"/>
                <ref-count count="23"/>
                <page-count count="0"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="introduction">
              <title>INTRODUCTION</title>
              <p>Patients with locally advanced or metastatic urothelial carcinoma (UC) have high recurrence rates following first-line platinum-based chemotherapy and poor prognosis.<sup><xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b2" ref-type="bibr">2</xref></sup> Second-line treatments include immunotherapy and antibody-drug conjugates, with three immune checkpoint inhibitors approved by the US Food and Drug Administration in this setting.<sup><xref rid="b1" ref-type="bibr">1</xref>-<xref rid="b4" ref-type="bibr">4</xref></sup> The pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib is approved for patients with susceptible <italic toggle="yes">FGFR3</italic> or <italic toggle="yes">FGFR2</italic> alterations following a phase II study reporting a 40% objective response rate (ORR) and median progression-free survival (PFS) and overall survival (OS) of 5.5 and 13.8 months, respectively.<sup><xref rid="b5" ref-type="bibr">5</xref>,<xref rid="b6" ref-type="bibr">6</xref></sup> Despite new options, many patients do not benefit from immunotherapy,<sup><xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b2" ref-type="bibr">2</xref></sup> and metastatic UC remains a deadly disease in patients who relapse or progress during first-line chemotherapy.</p>
              <boxed-text id="B1" position="anchor">
                <sec sec-type="context-box">
                  <title>CONTEXT</title>
                  <p>
                    <list list-type="simple">
                      <list-item>
                        <p>
                          <bold>Key Objective</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>This interim analysis of the phase II FORT-1 trial evaluated the efficacy and safety of the fibroblast growth factor receptor (FGFR) inhibitor rogaratinib versus chemotherapy in patients with advanced or metastatic urothelial carcinoma selected on the basis of overexpression of <italic toggle="yes">FGFR1</italic> or <italic toggle="yes">FGFR3</italic> mRNA previously treated with platinum chemotherapy.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Knowledge Generated</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>Comparable efficacy outcomes were observed with rogaratinib versus chemotherapy in patients selected on the basis of <italic toggle="yes">FGFR1</italic>/<italic toggle="yes">3</italic> mRNA positivity. An exploratory analysis suggested that rogaratinib may yield greater antitumor benefit in patients with both <italic toggle="yes">FGFR3</italic> mRNA overexpression and an <italic toggle="yes">FGFR</italic> DNA alteration, warranting further investigation.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Relevance</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>To our knowledge, these are the first reported data comparing FGFR-targeted therapy with standard-of-care chemotherapy in patients selected on the basis of <italic toggle="yes">FGFR</italic> mRNA-positive urothelial carcinoma.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
              <p>Aberrant activation of FGFR signaling by genetic alterations affects tumorigenesis and progression of various cancers, including late-stage muscle-invasive UC.<sup><xref rid="b7" ref-type="bibr">7</xref>-<xref rid="b9" ref-type="bibr">9</xref></sup> Of the four known FGFR subtypes, <italic toggle="yes">FGFR3</italic> mutations have been identified in up to 42% of all UCs, up to 20% of metastatic disease cases, and up to 15% of muscle-invasive bladder tumors.<sup><xref rid="b9" ref-type="bibr">9</xref>-<xref rid="b12" ref-type="bibr">12</xref></sup> However, one study showed that 42% of bladder tumors without a detectable <italic toggle="yes">FGFR3</italic> DNA mutation had FGFR3 protein overexpression, suggesting that patients with wild-type or <italic toggle="yes">FGFR3</italic>-mutated tumors could benefit from FGFR-targeted therapies.<sup><xref rid="b11" ref-type="bibr">11</xref></sup> Activating mutations in <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">RAS</italic> have been associated with resistance to FGFR inhibition in solid tumors, including UC,<sup><xref rid="b13" ref-type="bibr">13</xref>-<xref rid="b16" ref-type="bibr">16</xref></sup> implying that patients with wild-type <italic toggle="yes">PIK3CA</italic> or <italic toggle="yes">RAS</italic> may demonstrate improved responses to FGFR inhibition.</p>
              <p>Rogaratinib (Bayer AG, Berlin, Germany) is an oral FGFR1-4 inhibitor that showed promising efficacy and safety in a phase I study (ClinicalTrials.gov identifier: <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT01976741" ext-link-type="uri">NCT01976741</ext-link>) of patients with advanced cancers selected on the basis of <italic toggle="yes">FGFR1-3</italic> mRNA overexpression and/or <italic toggle="yes">FGFR3</italic>-activating mutations/translocations.<sup><xref rid="b17" ref-type="bibr">17</xref></sup> ORR was 24% (12/51) in a subset of patients with advanced muscle-invasive UC. Retrospective analysis supported the association of <italic toggle="yes">PIK3CA</italic> or <italic toggle="yes">RAS</italic> mutations with resistance to FGFR inhibition.<sup><xref rid="b17" ref-type="bibr">17</xref></sup></p>
              <p>We present the results from an unplanned interim analysis of the phase II part of FORT-1 (ClinicalTrials.gov identifier: <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT03410693" ext-link-type="uri">NCT03410693</ext-link>), a phase II/III, randomized, open-label study evaluating rogaratinib efficacy versus chemotherapy in patients with <italic toggle="yes">FGFR</italic> mRNA-positive advanced or metastatic UC previously treated with platinum chemotherapy.</p>
            </sec>
            <sec sec-type="methods">
              <title>METHODS</title>
              <sec sec-type="subjects">
                <title>Study Design and Patients</title>
                <p>This prospective, phase II, randomized, open-label, multicenter trial comprised <italic toggle="yes">FGFR</italic> testing, screening, treatment, and follow-up (Data Supplement, online only). The study was conducted at 161 academic medical centers/hospitals in Asia, Europe, North America, and Australia. <italic toggle="yes">FGFR</italic> testing was performed at the investigator's discretion ≤ 90 days before screening in patients age ≥ 18 years with locally advanced or metastatic UC, histologically or cytologically confirmed (including urinary bladder, renal pelvis, ureters, and urethra). Patients had to have an Eastern Cooperative Oncology Group performance status of 0 or 1 and availability of archival or fresh tumor biopsy. Only patients with <italic toggle="yes">FGFR1</italic>/<italic toggle="yes">3</italic> mRNA-positive tumors (high expression of <italic toggle="yes">FGFR1</italic> or <italic toggle="yes">FGFR3</italic> mRNA) were eligible to continue screening (Data Supplement).</p>
                <p>All patients provided written, informed consent. The study site designated Institutional Review Board or equivalent approved the Protocol (online only) before the start of the study, according to Good Clinical Practice guidelines and the Declaration of Helsinki.</p>
              </sec>
              <sec>
                <title>Random Assignment</title>
                <p>Eligible patients with <italic toggle="yes">FGFR1</italic>/<italic toggle="yes">3</italic> mRNA-expressing tumors were randomly assigned 1:1 to rogaratinib or investigator-determined intravenous chemotherapy. Random assignment was stratified by the presence/absence of <italic toggle="yes">PIK3CA</italic>-/<italic toggle="yes">RAS</italic>-activating mutations, presence/absence of previous immunotherapy, and high/low modified four-factor Bellmunt risk score.<sup><xref rid="b18" ref-type="bibr">18</xref></sup></p>
              </sec>
              <sec sec-type="methods">
                <title>Procedures</title>
                <p>We centrally assessed <italic toggle="yes">FGFR1</italic> or <italic toggle="yes">FGFR3</italic> mRNA expression using in situ hybridization (RNAscope; developed by Advanced Cell Diagnostics, Newark, CA, in partnership with Leica Biosystems, Newcastle, United Kingdom), with high <italic toggle="yes">FGFR</italic> mRNA expression defined as an RNAscope score of 3+ or 4+.<sup><xref rid="b17" ref-type="bibr">17</xref></sup> During <italic toggle="yes">FGFR</italic> testing, we centrally tested DNA from tumor biopsies for <italic toggle="yes">PIK3CA</italic> and/or <italic toggle="yes">RAS</italic> mutations using polymerase chain reaction–based clinical trial assays (LabCorp, Burlington, NC). Because of lower-than-expected prevalence of <italic toggle="yes">PIK3CA</italic> and/or <italic toggle="yes">RAS</italic> resistance mutations, we reconfirmed absence or presence in all enrolled patients using a targeted Illumina MiSeq panel (Illumina, Inc, San Diego, CA) performed by TARGOS Molecular Pathology GmbH (Kassel, Germany). Exploratory <italic toggle="yes">FGFR3</italic> DNA mutation and fusion testing used the OmniSeq Comprehensive targeted next-generation sequencing panel (OmniSeq, Buffalo, NY), with a minor allele frequency cutoff of 5%.</p>
                <p>The starting dose of rogaratinib was 800 mg orally twice daily in continuous 3-week cycles. Chemotherapy could include intravenous docetaxel 75 mg/m<sup>2</sup>, paclitaxel 175 mg/m<sup>2</sup>, or vinflunine 320 mg/m<sup>2</sup> once every 3 weeks. Patients continued treatment until radiologic or clinical disease progression, unacceptable toxicity, or withdrawal.</p>
                <p>We centrally assessed tumors using Response Evaluation Criteria in Solid Tumors version 1.1 at baseline, every 6 weeks up to week 18, and every 9 weeks thereafter. Assessments continued for at least 30 days for patients who discontinued treatment without disease progression.</p>
                <p>We collected blood samples for biomarker analyses at screening, before dosing on day 1 of each cycle, and within 14 days of discontinuation, and plasma samples for pharmacokinetic assessment in patients treated with rogaratinib on day 1 of cycles 1-5 before dosing and 0.5-1.5 hours after dosing.</p>
              </sec>
              <sec>
                <title>Outcomes</title>
                <p>The primary end point for the planned phase II/III study was OS. Secondary end points included PFS, ORR, disease control rate (DCR), duration of response, safety, and tolerability. Safety was assessed throughout the treatment period, within 14 days of discontinuation, and up to 30 days after the last study treatment, including evaluation for retinopathy. Grade ≥ 2 retinal disorders were considered of special interest and monitored throughout the study (Data Supplement). Treatment-emergent adverse events (TEAEs) were classified using Medical Dictionary for Regulatory Activities version 22.1 and graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.</p>
              </sec>
              <sec>
                <title>Statistical Analyses</title>
                <p>The phase II part of the study was designed to achieve 90% power to detect the difference in ORR between rogaratinib (assumed ORR = 30%) and chemotherapy (assumed ORR = 10%) in patients who were <italic toggle="yes">FGFR</italic> mRNA-positive with wild-type <italic toggle="yes">PIK3CA</italic>/<italic toggle="yes">RAS</italic>. Assuming a one-sided alpha of 0.1, a power of 90%, a mutation rate of approximately 25% for <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">RAS</italic> in the study population, and a random assignment ratio of 1:1, approximately 116 such patients were to be included in the planned analysis of ORR, on the basis of Fisher's exact test. phase II was planned to end after these first 116 enrolled patients completed 4.5 months of treatment, at which time the planned ORR analysis would be performed. Patients recruited to phase II were to automatically continue to phase III without interruption if futility was not demonstrated (Data Supplement).</p>
                <p>We analyzed efficacy in all randomly assigned patients (full analysis set). The safety population comprised patients who received ≥ 1 dose of study treatment. ORR and DCR were compared using Fisher's exact test. Median OS and PFS were estimated using Kaplan-Meier methods. Hazard ratios and 95% CIs for OS and PFS were calculated using stratified Cox proportional hazards and a stratified log-rank test. Median follow-up time was calculated using the reverse Kaplan-Meier method.</p>
                <p>Following a potential imbalance of deaths during the study period, the Data Monitoring Committee recommended a pause in enrollment and a reduction in the daily dose of rogaratinib from 800 to 600 mg twice daily for further evaluation. Because of similar efficacy between the treatment groups, the sponsor decided to stop further enrollment into the study on March 8, 2019. This report describes an interim analysis of efficacy and safety at a data cutoff date of November 25, 2019 (Data Supplement).</p>
                <p>We performed a retrospective exploratory rescoring of the tumor samples from randomly assigned patients because of a higher-than-expected proportion of patients testing positive for tumors with high <italic toggle="yes">FGFR1</italic> or <italic toggle="yes">FGFR3</italic> mRNA expression (RNAscope score 3+ or 4+; Data Supplement). We analyzed the relationship between rogaratinib exposure and safety using logistic regression models (Data Supplement).</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <sec sec-type="subjects">
                <title>Patients</title>
                <p>From May 31, 2018, to March 8, 2019, we tested 683 patients for <italic toggle="yes">FGFR1</italic>/<italic toggle="yes">3</italic> mRNA overexpression and 664 (97.2%) had a valid test result. Of these, 456 (68.7%) had <italic toggle="yes">FGFR</italic> overexpression at initial testing; 175 of these patients met the screening eligibility criteria, with 87 randomly assigned to rogaratinib and 88 to chemotherapy (Data Supplement). Of the 82 patients treated with chemotherapy, 40 (48.8%) received vinflunine, 24 (29.3%) received paclitaxel, and 18 (22.0%) received docetaxel. Overall, 7.4% of patients had wild-type <italic toggle="yes">PIK3CA</italic>/<italic toggle="yes">RAS</italic>, 10.9% were confirmed to have <italic toggle="yes">PIK3CA</italic> and/or <italic toggle="yes">RAS</italic> mutations, and 17.7% were unknown (Table <xref rid="tbl1" ref-type="table">1</xref>). A higher percentage of patients receiving rogaratinib had stage IV B disease at study entry (Table <xref rid="tbl1" ref-type="table">1</xref>).</p>
                <table-wrap position="float" id="tbl1">
                  <label>TABLE 1.</label>
                  <caption>
                    <p>Patient Demographics and Baseline Cancer Characteristics</p>
                  </caption>
                  <graphic xlink:href="jco-41-629-g001" position="float"/>
                </table-wrap>
              </sec>
              <sec>
                <title>Treatment</title>
                <p>At the cutoff date (median follow-up 10.8 months; 95% CI, 10.1 to 11.7), median treatment duration was 12.0 weeks (range, 2.1-40.7 weeks) with rogaratinib and 9.4 weeks (range, 0.1-39.1 weeks) with chemotherapy, corresponding to a median of four treatment cycles (range, 1-14 cycles) in both treatment groups. One patient (1.1%) assigned to rogaratinib and six (6.8%) assigned to chemotherapy did not receive treatment and were excluded from the safety analyses. Most patients receiving rogaratinib (83/86 [96.5%]) had a starting dose of 800 mg. At the analysis cutoff date, six patients (6.9%) were ongoing with rogaratinib and four (4.5%) were ongoing with chemotherapy. The most common primary reason for treatment discontinuation was disease progression, including radiologic progression in 53 patients (60.9%) receiving rogaratinib and 47 (53.4%) receiving chemotherapy, and clinical progression in zero and six (6.8%) patients, respectively.</p>
              </sec>
              <sec>
                <title>Efficacy</title>
                <p>In the overall population, ORRs of 20.7% (18/87) and 19.3% (17/88) were observed for patients assigned to rogaratinib and chemotherapy, respectively (rate difference = 1.4; one-sided <italic toggle="yes">P</italic> = .48), with similar DCRs between groups (Table <xref rid="tbl2" ref-type="table">2</xref>). Efficacy was similar in patients whose <italic toggle="yes">FGFR</italic> expression was confirmed by retrospective exploratory rescoring compared with the overall population (Data Supplement). Of responders, 12/18 (66.7%) assigned to rogaratinib and 9/17 (52.9%) assigned to chemotherapy had previously received immunotherapy.</p>
                <table-wrap position="float" id="tbl2">
                  <label>TABLE 2.</label>
                  <caption>
                    <p>Objective Tumor Response (full analysis set)</p>
                  </caption>
                  <graphic xlink:href="jco-41-629-g002" position="float"/>
                </table-wrap>
                <p>Median duration of response was 4.9 months (95% CI, 3.5 to 9.1) with rogaratinib and 5.8 months (95% CI, 3.5 to 7.7) with chemotherapy. Median OS was 8.3 months (95% CI, 6.5 to not evaluable) with rogaratinib and 9.8 months (95% CI, 6.8 to not evaluable) with chemotherapy (one-sided <italic toggle="yes">P</italic> = .67; Fig <xref rid="fig1" ref-type="fig">1</xref>A). Median PFS was similar (Fig <xref rid="fig1" ref-type="fig">1</xref>B). No differences in ORR or DCR were observed in the subset of patients with confirmed <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">RAS</italic> mutations (Data Supplement).</p>
                <fig position="float" id="fig1" fig-type="figure">
                  <label>FIG 1.</label>
                  <caption>
                    <p>Kaplan-Meier curves of (A) OS and (B) PFS (full analysis set). Median (95% CI) from Kaplan-Meier estimates; <italic toggle="yes">P</italic> value is taken from stratified log-rank test; HR (95% CI) on the basis of stratified Cox proportional hazards model. HR, hazard ratio; NE, not evaluable; OS, overall survival; PFS, progression-free survival.</p>
                  </caption>
                  <graphic xlink:href="jco-41-629-g003" position="float"/>
                </fig>
                <p>A post hoc analysis of patients with high <italic toggle="yes">FGFR3</italic> mRNA expression identified 21/82 (25.6%) assigned to rogaratinib and 15/79 (19.0%) assigned to chemotherapy who also had <italic toggle="yes">FGFR3</italic> DNA alterations (four unique hotspot mutations [<italic toggle="yes">FGFR3</italic>-G370C, <italic toggle="yes">FGFR3</italic>-R248C, <italic toggle="yes">FGFR3</italic>-S249C, and <italic toggle="yes">FGFR3</italic>-Y373C] and two unique fusions [<italic toggle="yes">FGFR3</italic>-TACC3v1 and <italic toggle="yes">FGFR3</italic>-TACC3v3]). Retrospective exploratory analysis showed higher ORRs for patients assigned to rogaratinib than to chemotherapy (Table <xref rid="tbl3" ref-type="table">3</xref>). Median OS at the later data cutoff was not reached in either group in this subset of patients (Data Supplement).</p>
                <table-wrap position="float" id="tbl3">
                  <label>TABLE 3.</label>
                  <caption>
                    <p>Exploratory Analysis of Tumor Response by <italic toggle="yes">FGFR3</italic> DNA Alteration (full analysis set)</p>
                  </caption>
                  <graphic xlink:href="jco-41-629-g004" position="float"/>
                </table-wrap>
              </sec>
              <sec>
                <title>Safety</title>
                <p>Grade 3 TEAEs occurred in 37 patients (43.0%) receiving rogaratinib and 32 (39.0%) receiving chemotherapy; grade 4 events occurred in 4 (4.7%) and 15 (18.3%), respectively (Table <xref rid="tbl4" ref-type="table">4</xref>). Grade ≥ 2 retinal disorders were reported in six patients (7.0%) with rogaratinib and zero patients with chemotherapy; events included retinal pigment epithelium detachment in three patients (3.5%; all grade 2) and chorioretinopathy (grade 2), retinopathy (grade 3), and serous retinopathy (grade 2) in one patient each (1.2%). Including grade 1 events, 26 patients (30.2%) receiving rogaratinib and three (3.7%) receiving chemotherapy experienced a retinal disorder (Data Supplement). TEAEs remained similar following rescoring of <italic toggle="yes">FGFR</italic> expression (Data Supplement). Table <xref rid="tbl5" ref-type="table">5</xref> summarizes drug-related TEAEs.</p>
                <table-wrap position="float" id="tbl4">
                  <label>TABLE 4.</label>
                  <caption>
                    <p>Summary of Most Common Any-Grade TEAEs Occurring in ≥ 10% of Patients in Either Treatment Group (safety analysis set<sup>a</sup>)</p>
                  </caption>
                  <graphic xlink:href="jco-41-629-g005" position="float"/>
                </table-wrap>
                <table-wrap position="float" id="tbl5">
                  <label>TABLE 5.</label>
                  <caption>
                    <p>Summary of Most Common Drug-Related Any-Grade TEAEs Occurring in ≥ 10% of Patients in Either Treatment Group (safety analysis set<sup>a</sup>)</p>
                  </caption>
                  <graphic xlink:href="jco-41-629-g006" position="float"/>
                </table-wrap>
                <p>Grade 5 TEAEs occurred in 19 patients (11.3%), 14 of whom (16.3%) received rogaratinib and five of whom (6.1%) received chemotherapy. The most common grade 5 events with rogaratinib were general physical health deterioration (n = 3) and dyspnea (n = 3), with no events considered drug-related. One grade 5 event in a patient receiving chemotherapy (respiratory tract infection) was considered drug-related. Of patients with grade 5 TEAEs, 11/14 (78.6%) receiving rogaratinib and 4/5 (80.0%) receiving chemotherapy had stage IV B disease at study entry. The Data Supplement provides further details on deaths during the study.</p>
                <p>An exploratory analysis showed no significant relationships between area under the curve from 0 to 12 hours at steady state and adverse events such as diarrhea, vomiting, nausea, fatigue, retinal disorder, nail disorder, and increased serum lipase, or between exposure and grade ≥ 3 TEAEs (Data Supplement).</p>
                <p>The Data Supplement summarizes dose modifications (interruptions or reductions). The most common TEAEs leading to dose modification were hyperphosphatemia (n = 18 [20.9%]) and diarrhea (n = 10 [11.6%]) with rogaratinib, and neutropenia/decreased neutrophil count (n = 6 [7.3%]) and fatigue (n = 4 [4.9%]) with chemotherapy. TEAEs led to permanent discontinuation in 15 patients (17.4%) receiving rogaratinib, most commonly asthenia in four patients (4.7%), with all other events occurring in one patient each (1.2%), and nine patients (11.0%) receiving chemotherapy, most commonly constipation, fatigue, and peripheral neuropathy in two patients each (2.4%).</p>
                <p>TEAE incidence was similar for those who received the planned rogaratinib dose of 800 mg twice daily or the reduced dose of 600 mg twice daily.</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>Interim results from the phase II part of the FORT-1 study of rogaratinib versus chemotherapy provide, to our knowledge, the first reported data comparing FGFR-targeted therapy with standard-of-care chemotherapy in patients selected for <italic toggle="yes">FGFR</italic> mRNA-positive UC, defined as overexpression of <italic toggle="yes">FGFR1</italic> or <italic toggle="yes">FGFR3</italic> mRNA.</p>
              <p>This interim analysis of 175 patients revealed no significant differences in ORRs between patients assigned to rogaratinib or chemotherapy (20.7% and 19.3%, respectively). The ORR observed with rogaratinib is comparable with that in the subset of patients with UC selected on the basis of <italic toggle="yes">FGFR1-3</italic> mRNA overexpression in the phase I study of rogaratinib (23.5%),<sup><xref rid="b17" ref-type="bibr">17</xref></sup> and is in line with ORRs reported in early-phase trials of other pan-FGFR inhibitors in patients with UC with <italic toggle="yes">FGFR3</italic> mutations.<sup><xref rid="b19" ref-type="bibr">19</xref>,<xref rid="b20" ref-type="bibr">20</xref></sup> Similarly, no significant differences in DCRs were observed in the rogaratinib and chemotherapy groups. The DCR observed with rogaratinib was slightly lower than that reported in other studies of early-phase FGFR inhibitors in patients with advanced UC selected on the basis of <italic toggle="yes">FGFR3</italic> DNA alterations<sup><xref rid="b19" ref-type="bibr">19</xref>,<xref rid="b20" ref-type="bibr">20</xref></sup> and in the phase I study of rogaratinib (71% overall and 73% in the subset with UC).<sup><xref rid="b17" ref-type="bibr">17</xref></sup></p>
              <p>OS and PFS were not statistically different within the treatment groups. OS with rogaratinib in patients selected on the basis of high expression of <italic toggle="yes">FGFR1</italic>/<italic toggle="yes">3</italic> mRNA was broadly similar to that reported with the FGFR1-3 inhibitor infigratinib in patients with advanced UC with <italic toggle="yes">FGFR3</italic> genetic alterations (7.75 months), with a comparable duration of treatment.<sup><xref rid="b19" ref-type="bibr">19</xref></sup> PFS was similar to that in the phase I study of rogaratinib (3.3 months).<sup><xref rid="b17" ref-type="bibr">17</xref></sup> In a phase II trial of the pan-FGFR inhibitor erdafitinib in patients with platinum-refractory advanced UC selected on the basis of <italic toggle="yes">FGFR</italic> DNA alterations, median OS and PFS were 13.8 and 5.5 months, respectively.<sup><xref rid="b5" ref-type="bibr">5</xref></sup> Our findings show that patient selection on the basis of <italic toggle="yes">FGFR1</italic> or <italic toggle="yes">FGFR3</italic> mRNA positivity alone does not lead to improved outcomes with rogaratinib versus chemotherapy.</p>
              <p>Following a higher-than-expected proportion of patients having tumors with high <italic toggle="yes">FGFR1</italic> and <italic toggle="yes">FGFR3</italic> mRNA expression (69% in this study <italic toggle="yes">v</italic> 50% in the phase I study<sup><xref rid="b17" ref-type="bibr">17</xref></sup>), we performed a retrospective exploratory rescoring of tumor samples from randomly assigned patients; efficacy and safety were not significantly affected by this rescoring (Data Supplement). However, we cannot rule out the possibility that patients without high <italic toggle="yes">FGFR1</italic> and <italic toggle="yes">FGFR3</italic> mRNA expression were included in the study, potentially contributing to the limited objective responses with rogaratinib.</p>
              <p>Because of the small proportion of patients with confirmed <italic toggle="yes">PIK3CA</italic>/<italic toggle="yes">RAS</italic> mutations, it was not possible to robustly test if wild-type <italic toggle="yes">PIK3CA</italic>/<italic toggle="yes">RAS</italic> was associated with improved responses to FGFR inhibition compared with patients with activating mutations. Previous observations linking <italic toggle="yes">PIK3CA</italic>- and <italic toggle="yes">RAS</italic>-activating mutations with resistance to FGFR inhibition in solid tumors, including UC,<sup><xref rid="b13" ref-type="bibr">13</xref>-<xref rid="b16" ref-type="bibr">16</xref></sup> indicate that this hypothesis may be worthy of investigation.</p>
              <p>Retrospective exploratory analysis of patients positive for <italic toggle="yes">FGFR3</italic> mRNA and with <italic toggle="yes">FGFR3</italic> DNA alterations revealed a higher ORR with rogaratinib compared with the full analysis set (52.4% <italic toggle="yes">v</italic> 20.7%). An ORR of 40% was observed with erdafitinib in patients with advanced UC selected on the basis of <italic toggle="yes">FGFR</italic> DNA alterations.<sup><xref rid="b5" ref-type="bibr">5</xref></sup> In our study, median OS was not reached in either group in patients with <italic toggle="yes">FGFR3</italic> DNA alterations, but survival was slightly lower with rogaratinib compared with chemotherapy. However, these ORR and OS results should be interpreted with caution because of the small sample size and retrospective exploratory nature. Overall, the improved ORR with rogaratinib seen in this study in <italic toggle="yes">FGFR</italic> mRNA-positive patients with <italic toggle="yes">FGFR</italic> genetic DNA alterations is of interest and may warrant further evaluation.</p>
              <p>GI toxicities were among the most commonly observed TEAEs, in line with the phase I study of rogaratinib<sup><xref rid="b17" ref-type="bibr">17</xref></sup> and other studies of pan-FGFR inhibitors in patients with advanced UC.<sup><xref rid="b5" ref-type="bibr">5</xref>,<xref rid="b19" ref-type="bibr">19</xref>,<xref rid="b20" ref-type="bibr">20</xref></sup> Hyperphosphatemia was the second most common TEAE with rogaratinib and is considered an on-target effect of FGFR inhibition related to FGFR2/3 signaling<sup><xref rid="b21" ref-type="bibr">21</xref>,<xref rid="b22" ref-type="bibr">22</xref></sup>; no grade ≥ 3 events were reported, and all cases of hyperphosphatemia resolved with treatment interruption and were without clinically relevant symptoms. Grade ≥ 2 retinal disorders were considered TEAEs of special interest and were reported in 7.0% of patients receiving rogaratinib compared with zero receiving chemotherapy; 30.2% of patients receiving rogaratinib and 3.7% receiving chemotherapy experienced retinal disorders of any grade. An exploratory analysis showed no significant relationships between rogaratinib exposure and TEAEs. Dose modifications were more frequent with rogaratinib than with chemotherapy, partly because of protocol-mandated modifications for hyperphosphatemia.</p>
              <p>Grade 5 events were more common with rogaratinib than with chemotherapy (16.3% <italic toggle="yes">v</italic> 6.1%). Most grade 5 events across both groups were in patients with stage IV B disease at study entry, suggesting that these patients may have been at greater risk of TEAEs leading to death, irrespective of treatment group; the higher percentage of patients with stage IV B disease receiving rogaratinib may explain the slight imbalance in grade 5 events observed between groups. No grade 5 events were considered related to rogaratinib, and one case of grade 5 respiratory tract infection was attributed to chemotherapy. Potentially severe lung infection as a result of immune consequences is a known side effect of chemotherapy.<sup><xref rid="b23" ref-type="bibr">23</xref></sup></p>
              <p>In conclusion, to our knowledge, these are the first reported data comparing FGFR-directed therapy with chemotherapy in patients with <italic toggle="yes">FGFR</italic>-altered UC. Rogaratinib demonstrated efficacy comparable with standard chemotherapy and a manageable safety profile. Prespecified efficacy criteria were not met for continuation to phase III in this population. An exploratory analysis suggested that rogaratinib may have greater antitumor benefit in patients with both <italic toggle="yes">FGFR3</italic> mRNA overexpression and an <italic toggle="yes">FGFR</italic> DNA alteration, which warrants further investigation.</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>ACKNOWLEDGMENT</title>
              <p>The authors wish to thank the patients and their families, coinvestigators, and referring physicians who participated in this study. The authors thank Ashraf Yassen and Xiang Qing Yu of Bayer AG, and Jon Moss and Adam Lloyd of BAST Inc Limited, Kington, United Kingdom, for their expertise and assistance with pharmacometric evaluations, and Bingyan Wu of Bayer AG for her assistance with statistical analyses and outputs. Laura Valenzo, PhD, and Jake Stoddart, MRes, of Complete HealthVizion, McCann Health Medical Communications, provided medical writing support with this manuscript, on the basis of detailed discussion and feedback from all the authors; this assistance was funded by Bayer AG. RNAscope assay for <italic toggle="yes">FGFR</italic> expression was developed for use in this study by Leica Biosystems (Newcastle upon Tyne, United Kingdom).</p>
              <p>The list of FORT‐1 trial investigators who contributed to the success of the trial is available in Appendix <xref rid="tblA1" ref-type="table">Table A1</xref> (online only).</p>
            </ack>
            <fn-group content-type="presented-at">
              <title>PRIOR PRESENTATION</title>
              <fn specific-use="presented-at" fn-type="presented-at">
                <p>Presented in part at the 2020 ASCO Genitourinary Cancers Symposium, San Francisco, CA, February 13-15, 2020.</p>
              </fn>
            </fn-group>
            <fn-group content-type="supported-by">
              <title>SUPPORT</title>
              <fn specific-use="supported-by" fn-type="supported-by">
                <p>Supported by research funding from Bayer AG.</p>
              </fn>
            </fn-group>
            <fn-group content-type="trial">
              <title>CLINICAL TRIAL INFORMATION</title>
              <fn specific-use="trial" fn-type="other">
                <p>
                  <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT03410693" ext-link-type="uri">NCT03410693</ext-link>
                </p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability">
              <title>DATA SHARING STATEMENT</title>
              <p>Availability of the data underlying this publication will be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for Responsible Clinical Trial Data Sharing. This pertains to scope, time point, and process of data access.</p>
              <p>As such, Bayer commits to sharing upon request from qualified scientific and medical researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the United States and European Union as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 1, 2014.</p>
              <p>Interested researchers can use <ext-link xlink:href="http://www.clinicalstudydatarequest.com" ext-link-type="uri">www.clinicalstudydatarequest.com</ext-link> to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the study sponsor's section of the portal.</p>
              <p>Data access will be granted to anonymized patient-level data, protocols, and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that patient privacy is safeguarded.</p>
            </sec>
            <sec sec-type="contributed">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> Cora N. Sternberg, Daniel P. Petrylak, Joaquim Bellmunt, Weichao Bao, Peter Ellinghaus, Chengxing Lu, Sabine Coppieters, Keiko Nakajima, Tatiane Cristine Ishida, David I. Quinn</p>
              <p><bold>Administrative support:</bold> Tatiane Cristine Ishida</p>
              <p><bold>Provision of study materials or patients:</bold> Cora N. Sternberg, Joaquim Bellmunt, Howard Gurney, Jae-Lyun Lee, Michiel S. van der Heijden, Nicolas Penel, See-Tong Pang, Jian-Ri Li, Xavier García del Muro, Florence Joly, David I. Quinn</p>
              <p><bold>Collection and assembly of data:</bold> Cora N. Sternberg, Joaquim Bellmunt, Hiroyuki Nishiyama, Howard Gurney, Jae-Lyun Lee, Michiel S. van der Heijden, See-Tong Pang, Jian-Ri Li, Xavier García del Muro, Peter Ellinghaus, Chengxing Lu, Sabine Coppieters, Keiko Nakajima, Tatiane Cristine Ishida, David I. Quinn</p>
              <p><bold>Data analysis and interpretation:</bold> Cora N. Sternberg, Joaquim Bellmunt, Hiroyuki Nishiyama, Andrea Necchi, Howard Gurney, Jae-Lyun Lee, Michiel S. van der Heijden, Eli Rosenbaum, Nicolas Penel, Xavier García del Muro, Florence Joly, Weichao Bao, Peter Ellinghaus, Chengxing Lu, Mitchell Sierecki, Sabine Coppieters, Keiko Nakajima, Tatiane Cristine Ishida, David I. Quinn</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
              <p><bold>Accountable for all aspects of the work:</bold> All authors</p>
            </sec>
            <sec sec-type="disclosures">
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <sec>
                <title>FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <italic toggle="yes">FGFR1</italic>/<italic toggle="yes">3</italic> mRNA Expression</title>
                <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link xlink:href="http://www.asco.org/rwc" ext-link-type="uri">www.asco.org/rwc</ext-link> or <ext-link xlink:href="https://ascopubs.org/jco/authors/author-center" ext-link-type="uri">ascopubs.org/jco/authors/author-center</ext-link>.</p>
                <p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link xlink:href="https://openpaymentsdata.cms.gov/" ext-link-type="uri">Open Payments</ext-link>).</p>
                <fn-group content-type="COI-statement">
                  <fn id="con1" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Jae-Lyun Lee</bold>
                    </p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Myovant Sciences, Johnson &amp; Johnson/Janssen, Amgen, Merck, BeiGene, Innovent Biologics, Black Diamond Therapeutics, Karyopharm Therapeutics, Zymeworks</p>
                    <p><bold>Honoraria:</bold> Bristol Myers Squibb, Astellas Pharma, Pfizer, AstraZeneca, MSD</p>
                    <p><bold>Consulting or Advisory Role:</bold> Pfizer, BMS Korea, GI Innovation, MSD, Merck, AstraZeneca, Sanofi, Oscotec</p>
                    <p><bold>Research Funding:</bold> Pfizer (Inst), Janssen (Inst), Novartis (Inst), Bristol Myers Squibb (Inst), Roche/Genentech (Inst), AstraZeneca/MedImmune (Inst), MSD (Inst), Bayer Schering Pharma (Inst), Seattle Genetics (Inst), GI Innovation (Inst), Amgen (Inst)</p>
                  </fn>
                  <fn id="con2" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Tatiane Cristine Ishida</bold>
                    </p>
                    <p><bold>Employment:</bold> Bayer</p>
                  </fn>
                  <fn id="con3" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Hiroyuki Nishiyama</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> MSD, Chugai Pharma, Bayer Yakuhin, Janssen, Lilly</p>
                    <p><bold>Speakers' Bureau:</bold> MSD, Chugai Pharma, Astellas Pharma</p>
                    <p><bold>Research Funding:</bold> Astellas Pharma (Inst), Ono Pharmaceutical (Inst), Takeda (Inst), Bayer Yakuhin (Inst)</p>
                  </fn>
                  <fn id="con4" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Sabine Coppieters</bold>
                    </p>
                    <p><bold>Employment:</bold> Bayer, Argenx</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Bayer, Argenx</p>
                  </fn>
                  <fn id="con5" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Michiel S. van der Heijden</bold>
                    </p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Gilead Sciences</p>
                    <p><bold>Consulting or Advisory Role:</bold> Roche/Genentech (Inst), Astellas Pharma (Inst), AstraZeneca/MedImmune (Inst), Bristol Myers Squibb (Inst), MSD Oncology (Inst), Seattle Genetics (Inst), Janssen (Inst), Pfizer (Inst)</p>
                    <p><bold>Research Funding:</bold> Astellas Pharma (Inst), Bristol Myers Squibb (Inst), Roche (Inst), AstraZeneca (Inst), Seattle Genetics (Inst), 4SC (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Novartis, Astellas Pharma, MSD Oncology, Roche</p>
                  </fn>
                  <fn id="con6" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Weichao Bao</bold>
                    </p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Bayer (Inst)</p>
                  </fn>
                  <fn id="con7" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>David I. Quinn</bold>
                    </p>
                    <p><bold>Employment:</bold> AbbVie</p>
                    <p><bold>Honoraria:</bold> Bayer, Pfizer, Genentech/Roche, Merck Sharp &amp; Dohme, Bristol Myers Squibb, Exelixis, Seattle Genetics, Myovant Sciences, AVEO, Clinigen Group</p>
                    <p><bold>Consulting or Advisory Role:</bold> Pfizer, Bristol Myers Squibb, Genentech/Roche, Merck Sharp &amp; Dohme, Bayer, Exelixis, Eisai, US Biotest, Seattle Genetics, Myovant Sciences, AVEO, Clinigen Group</p>
                    <p><bold>Research Funding:</bold> Genentech/Roche (Inst), Merck (Inst), Pfizer (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Bayer, Exelixis</p>
                    <p><bold>Uncompensated Relationships:</bold> Eisai, US Biotest</p>
                  </fn>
                  <fn id="con8" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Howard Gurney</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Bristol Myers Squibb, Ipsen, Merck Sharp &amp; Dohme, AstraZeneca, Janssen-Cilag, Pfizer, Roche, Merck Serono, Astellas Pharma</p>
                    <p><bold>Speakers' Bureau:</bold> Merck Serono</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> AstraZeneca</p>
                  </fn>
                  <fn id="con9" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Florence Joly</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> AstraZeneca, Janssen, Ipsen, Pfizer, MSD Oncology, Bristol Myers Squibb, GlaxoSmithKline, Astellas Pharma, Clovis Oncology, Amgen, Seattle Genetics, Bayer</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Janssen, AstraZeneca, Ipsen, GlaxoSmithKline, BMS</p>
                  </fn>
                  <fn id="con10" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Keiko Nakajima</bold>
                    </p>
                    <p><bold>Employment:</bold> Bayer, Daiichi Sankyo/Astra Zeneca</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Bayer, Daiichi Sankyo/Astra Zeneca</p>
                  </fn>
                  <fn id="con11" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Joaquim Bellmunt</bold>
                    </p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Rainier Therapeutics</p>
                    <p><bold>Honoraria:</bold> UpToDate</p>
                    <p><bold>Consulting or Advisory Role:</bold> Pierre Fabre, Astellas Pharma, Pfizer, Merck, Genentech, Novartis, AstraZeneca/MedImmune, Bristol Myers Squibb</p>
                    <p><bold>Research Funding:</bold> Millennium (Inst), Sanofi (Inst), Pfizer/EMD Serono (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Pfizer, MSD Oncology, Ipsen</p>
                  </fn>
                  <fn id="con12" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Mitchell Sierecki</bold>
                    </p>
                    <p><bold>Employment:</bold> Gilead Sciences, Bayer HealthCare Pharmacuticals</p>
                    <p><bold>Leadership:</bold> Gilead Sciences, Bayer HealthCare Pharmacuticals</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Gilead Sciences</p>
                  </fn>
                  <fn id="con13" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Andrea Necchi</bold>
                    </p>
                    <p><bold>Employment:</bold> Bayer</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Bayer</p>
                    <p><bold>Honoraria:</bold> Roche, Merck, AstraZeneca, Janssen, Foundation Medicine, Bristol Myers Squibb</p>
                    <p><bold>Consulting or Advisory Role:</bold> Merck Sharp &amp; Dohme, Roche, Bayer, AstraZeneca, Clovis Oncology, Janssen, Incyte, Seattle Genetics/Astellas, Bristol Myers Squibb, Rainier Therapeutics, GlaxoSmithKline, Ferring</p>
                    <p><bold>Research Funding:</bold> Merck Sharp &amp; Dohme (Inst), AstraZeneca (Inst), Ipsen, Seattle Genetics (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Roche, Merck Sharp &amp; Dohme, AstraZeneca, Janssen, Rainier Therapeutics</p>
                    <p><bold>Other Relationship:</bold> Bayer</p>
                  </fn>
                  <fn id="con14" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Xavier García del Muro</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Pfizer, Bristol Myers Squibb, Ipsen, Roche, Lilly, PharmaMar, EUSA Pharma, GlaxoSmithKline, Merck, Eisai</p>
                    <p><bold>Speakers' Bureau:</bold> Pfizer, Bristol Myers Squibb, Astellas Pharma, Eisai</p>
                    <p><bold>Research Funding:</bold> AstraZeneca</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Pfizer, Roche</p>
                  </fn>
                  <fn id="con15" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Cora N. Sternberg</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Bayer, MSD, Pfizer, Roche, Incyte, AstraZeneca, Merck, Medscape, UroToday, Astellas Pharma, Genzyme, Immunomedics, Foundation Medicine, Bristol Myers Squibb/Medarex, IMPAC Medical Systems</p>
                  </fn>
                  <fn id="con16" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Eli Rosenbaum</bold>
                    </p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Brainsway, Conergent</p>
                    <p><bold>Consulting or Advisory Role:</bold> MSD Oncology, Teva, Astellas Pharma, Bayer, Janssen</p>
                    <p><bold>Speakers' Bureau:</bold> MSD Oncology</p>
                  </fn>
                  <fn id="con17" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Peter Ellinghaus</bold>
                    </p>
                    <p><bold>Employment:</bold> Bayer</p>
                    <p><bold>Leadership:</bold> Bayer</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Bayer</p>
                  </fn>
                  <fn id="con18" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Daniel P. Petrylak</bold>
                    </p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Bellicum Pharmaceuticals, TYME</p>
                    <p><bold>Consulting or Advisory Role:</bold> Bayer, Exelixis, Pfizer, Roche, Astellas Pharma, AstraZeneca, Lilly, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Incyte, Janssen, Pharmacyclics, Seattle Genetics, Urogen pharma, Advanced Accelerator Applications, Ipsen, Bicycle Therapeutics, Mirati Therapeutics, Monopteros Therapeutics, Regeneron, Gilead Sciences</p>
                    <p><bold>Research Funding:</bold> Progenics (Inst), Sanofi (Inst), Endocyte (Inst), Genentech (Inst), Merck (Inst), Astellas Medivation (Inst), Novartis (Inst), AstraZeneca (Inst), Bayer (Inst), Lilly (Inst), Innocrin Pharma (Inst), MedImmune (Inst), Pfizer (Inst), Roche (Inst), Seattle Genetics (Inst), Clovis Oncology (Inst), Bristol Myers Squibb (Inst), Advanced Accelerator Applications (Inst), Agensys (Inst), BioXCel Therapeutics (Inst), Eisai (Inst), Mirati Therapeutics (Inst), Replimune (Inst), Medivation (Inst), Gilead Sciences (Inst)</p>
                    <p><bold>Expert Testimony:</bold> Celgene, Sanofi</p>
                  </fn>
                  <fn id="con19" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Nicolas Penel</bold>
                    </p>
                    <p><bold>Research Funding:</bold> Bayer (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Astellas Pharma, Janssen-Cilag</p>
                    <p><bold>Other Relationship:</bold> PharmaMar</p>
                  </fn>
                  <fn id="con20" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Chengxing Lu</bold>
                    </p>
                    <p><bold>Employment:</bold> Bayer, Biogen, AstraZeneca</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Bayer, Biogen, AstraZeneca</p>
                    <p>No other potential conflicts of interest were reported.</p>
                  </fn>
                </fn-group>
              </sec>
            </sec>
            <notes>
              <fn-group content-type="COI-statement">
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Jae-Lyun Lee</bold>
                  </p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Myovant Sciences, Johnson &amp; Johnson/Janssen, Amgen, Merck, BeiGene, Innovent Biologics, Black Diamond Therapeutics, Karyopharm Therapeutics, Zymeworks</p>
                  <p><bold>Honoraria:</bold> Bristol Myers Squibb, Astellas Pharma, Pfizer, AstraZeneca, MSD</p>
                  <p><bold>Consulting or Advisory Role:</bold> Pfizer, BMS Korea, GI Innovation, MSD, Merck, AstraZeneca, Sanofi, Oscotec</p>
                  <p><bold>Research Funding:</bold> Pfizer (Inst), Janssen (Inst), Novartis (Inst), Bristol Myers Squibb (Inst), Roche/Genentech (Inst), AstraZeneca/MedImmune (Inst), MSD (Inst), Bayer Schering Pharma (Inst), Seattle Genetics (Inst), GI Innovation (Inst), Amgen (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Tatiane Cristine Ishida</bold>
                  </p>
                  <p><bold>Employment:</bold> Bayer</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Hiroyuki Nishiyama</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> MSD, Chugai Pharma, Bayer Yakuhin, Janssen, Lilly</p>
                  <p><bold>Speakers' Bureau:</bold> MSD, Chugai Pharma, Astellas Pharma</p>
                  <p><bold>Research Funding:</bold> Astellas Pharma (Inst), Ono Pharmaceutical (Inst), Takeda (Inst), Bayer Yakuhin (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Sabine Coppieters</bold>
                  </p>
                  <p><bold>Employment:</bold> Bayer, Argenx</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Bayer, Argenx</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Michiel S. van der Heijden</bold>
                  </p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Gilead Sciences</p>
                  <p><bold>Consulting or Advisory Role:</bold> Roche/Genentech (Inst), Astellas Pharma (Inst), AstraZeneca/MedImmune (Inst), Bristol Myers Squibb (Inst), MSD Oncology (Inst), Seattle Genetics (Inst), Janssen (Inst), Pfizer (Inst)</p>
                  <p><bold>Research Funding:</bold> Astellas Pharma (Inst), Bristol Myers Squibb (Inst), Roche (Inst), AstraZeneca (Inst), Seattle Genetics (Inst), 4SC (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Novartis, Astellas Pharma, MSD Oncology, Roche</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Weichao Bao</bold>
                  </p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Bayer (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>David I. Quinn</bold>
                  </p>
                  <p><bold>Employment:</bold> AbbVie</p>
                  <p><bold>Honoraria:</bold> Bayer, Pfizer, Genentech/Roche, Merck Sharp &amp; Dohme, Bristol Myers Squibb, Exelixis, Seattle Genetics, Myovant Sciences, AVEO, Clinigen Group</p>
                  <p><bold>Consulting or Advisory Role:</bold> Pfizer, Bristol Myers Squibb, Genentech/Roche, Merck Sharp &amp; Dohme, Bayer, Exelixis, Eisai, US Biotest, Seattle Genetics, Myovant Sciences, AVEO, Clinigen Group</p>
                  <p><bold>Research Funding:</bold> Genentech/Roche (Inst), Merck (Inst), Pfizer (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Bayer, Exelixis</p>
                  <p><bold>Uncompensated Relationships:</bold> Eisai, US Biotest</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Howard Gurney</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Bristol Myers Squibb, Ipsen, Merck Sharp &amp; Dohme, AstraZeneca, Janssen-Cilag, Pfizer, Roche, Merck Serono, Astellas Pharma</p>
                  <p><bold>Speakers' Bureau:</bold> Merck Serono</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> AstraZeneca</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Florence Joly</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> AstraZeneca, Janssen, Ipsen, Pfizer, MSD Oncology, Bristol Myers Squibb, GlaxoSmithKline, Astellas Pharma, Clovis Oncology, Amgen, Seattle Genetics, Bayer</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Janssen, AstraZeneca, Ipsen, GlaxoSmithKline, BMS</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Keiko Nakajima</bold>
                  </p>
                  <p><bold>Employment:</bold> Bayer, Daiichi Sankyo/Astra Zeneca</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Bayer, Daiichi Sankyo/Astra Zeneca</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Joaquim Bellmunt</bold>
                  </p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Rainier Therapeutics</p>
                  <p><bold>Honoraria:</bold> UpToDate</p>
                  <p><bold>Consulting or Advisory Role:</bold> Pierre Fabre, Astellas Pharma, Pfizer, Merck, Genentech, Novartis, AstraZeneca/MedImmune, Bristol Myers Squibb</p>
                  <p><bold>Research Funding:</bold> Millennium (Inst), Sanofi (Inst), Pfizer/EMD Serono (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Pfizer, MSD Oncology, Ipsen</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Mitchell Sierecki</bold>
                  </p>
                  <p><bold>Employment:</bold> Gilead Sciences, Bayer HealthCare Pharmacuticals</p>
                  <p><bold>Leadership:</bold> Gilead Sciences, Bayer HealthCare Pharmacuticals</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Gilead Sciences</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Andrea Necchi</bold>
                  </p>
                  <p><bold>Employment:</bold> Bayer</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Bayer</p>
                  <p><bold>Honoraria:</bold> Roche, Merck, AstraZeneca, Janssen, Foundation Medicine, Bristol Myers Squibb</p>
                  <p><bold>Consulting or Advisory Role:</bold> Merck Sharp &amp; Dohme, Roche, Bayer, AstraZeneca, Clovis Oncology, Janssen, Incyte, Seattle Genetics/Astellas, Bristol Myers Squibb, Rainier Therapeutics, GlaxoSmithKline, Ferring</p>
                  <p><bold>Research Funding:</bold> Merck Sharp &amp; Dohme (Inst), AstraZeneca (Inst), Ipsen, Seattle Genetics (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Roche, Merck Sharp &amp; Dohme, AstraZeneca, Janssen, Rainier Therapeutics</p>
                  <p><bold>Other Relationship:</bold> Bayer</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Xavier García del Muro</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Pfizer, Bristol Myers Squibb, Ipsen, Roche, Lilly, PharmaMar, EUSA Pharma, GlaxoSmithKline, Merck, Eisai</p>
                  <p><bold>Speakers' Bureau:</bold> Pfizer, Bristol Myers Squibb, Astellas Pharma, Eisai</p>
                  <p><bold>Research Funding:</bold> AstraZeneca</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Pfizer, Roche</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Cora N. Sternberg</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Bayer, MSD, Pfizer, Roche, Incyte, AstraZeneca, Merck, Medscape, UroToday, Astellas Pharma, Genzyme, Immunomedics, Foundation Medicine, Bristol Myers Squibb/Medarex, IMPAC Medical Systems</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Eli Rosenbaum</bold>
                  </p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Brainsway, Conergent</p>
                  <p><bold>Consulting or Advisory Role:</bold> MSD Oncology, Teva, Astellas Pharma, Bayer, Janssen</p>
                  <p><bold>Speakers' Bureau:</bold> MSD Oncology</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Peter Ellinghaus</bold>
                  </p>
                  <p><bold>Employment:</bold> Bayer</p>
                  <p><bold>Leadership:</bold> Bayer</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Bayer</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Daniel P. Petrylak</bold>
                  </p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Bellicum Pharmaceuticals, TYME</p>
                  <p><bold>Consulting or Advisory Role:</bold> Bayer, Exelixis, Pfizer, Roche, Astellas Pharma, AstraZeneca, Lilly, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Incyte, Janssen, Pharmacyclics, Seattle Genetics, Urogen pharma, Advanced Accelerator Applications, Ipsen, Bicycle Therapeutics, Mirati Therapeutics, Monopteros Therapeutics, Regeneron, Gilead Sciences</p>
                  <p><bold>Research Funding:</bold> Progenics (Inst), Sanofi (Inst), Endocyte (Inst), Genentech (Inst), Merck (Inst), Astellas Medivation (Inst), Novartis (Inst), AstraZeneca (Inst), Bayer (Inst), Lilly (Inst), Innocrin Pharma (Inst), MedImmune (Inst), Pfizer (Inst), Roche (Inst), Seattle Genetics (Inst), Clovis Oncology (Inst), Bristol Myers Squibb (Inst), Advanced Accelerator Applications (Inst), Agensys (Inst), BioXCel Therapeutics (Inst), Eisai (Inst), Mirati Therapeutics (Inst), Replimune (Inst), Medivation (Inst), Gilead Sciences (Inst)</p>
                  <p><bold>Expert Testimony:</bold> Celgene, Sanofi</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Nicolas Penel</bold>
                  </p>
                  <p><bold>Research Funding:</bold> Bayer (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Astellas Pharma, Janssen-Cilag</p>
                  <p><bold>Other Relationship:</bold> PharmaMar</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="other">
                  <p>
                    <bold>Chengxing Lu</bold>
                  </p>
                  <p><bold>Employment:</bold> Bayer, Biogen, AstraZeneca</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Bayer, Biogen, AstraZeneca</p>
                  <p>No other potential conflicts of interest were reported.</p>
                </fn>
              </fn-group>
            </notes>
            <app-group>
              <app id="app1">
                <title>APPENDIX</title>
                <p>
                  <table-wrap position="anchor" id="tblA1">
                    <label>TABLE A1.</label>
                    <caption>
                      <p>FORT-1 Principal Investigators</p>
                    </caption>
                    <graphic xlink:href="jco-41-629-g007" position="float"/>
                  </table-wrap>
                </p>
              </app>
            </app-group>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="b1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dietrich</surname><given-names>B</given-names></name><name><surname>Siefker-Radtke</surname><given-names>AO</given-names></name><name><surname>Srinivas</surname><given-names>S</given-names></name><etal/></person-group>: <article-title>Systemic therapy for advanced urothelial carcinoma: Current standards and treatment considerations</article-title>. <source>Am Soc Clin Oncol Ed Book</source><volume>38</volume>:<fpage>342</fpage>-<lpage>353</lpage>, <year>2018</year></mixed-citation>
              </ref>
              <ref id="b2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadal</surname><given-names>R</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name></person-group>: <article-title>Management of metastatic bladder cancer</article-title>. <source>Cancer Treat Rev</source><volume>76</volume>:<fpage>10</fpage>-<lpage>21</lpage>, <year>2019</year><pub-id pub-id-type="pmid">31030123</pub-id></mixed-citation>
              </ref>
              <ref id="b3">
                <label>3.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>AstraZeneca</collab></person-group>: <source>Voluntary Withdrawal of Imfinzi Indication in Advanced Bladder Cancer in the US</source>, <year>2021</year>. <ext-link xlink:href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/voluntary-withdrawal-imfinzi-us-bladder-indication.html" ext-link-type="uri">https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/voluntary-withdrawal-imfinzi-us-bladder-indication.html</ext-link></mixed-citation>
              </ref>
              <ref id="b4">
                <label>4.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Roche</collab></person-group>: <source>Roche Provides Update on Tecentriq US Indication in Prior-Platinum Treated Metastatic Bladder Cancer</source>, <year>2021</year>. <ext-link xlink:href="https://www.roche.com/media/releases/med-cor-2021-03-08.htm" ext-link-type="uri">https://www.roche.com/media/releases/med-cor-2021-03-08.htm</ext-link></mixed-citation>
              </ref>
              <ref id="b5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loriot</surname><given-names>Y</given-names></name><name><surname>Necchi</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><etal/></person-group>: <article-title>Erdafitinib in locally advanced or metastatic urothelial carcinoma</article-title>. <source>N Engl J Med</source><volume>381</volume>:<fpage>338</fpage>-<lpage>348</lpage>, <year>2019</year><pub-id pub-id-type="pmid">31340094</pub-id></mixed-citation>
              </ref>
              <ref id="b6">
                <label>6.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>US Food and Drug Administration</collab></person-group>: <source>FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma</source>, <year>2019</year>. <ext-link xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma</ext-link></mixed-citation>
              </ref>
              <ref id="b7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>I</given-names></name><name><surname>Iwata</surname><given-names>T</given-names></name><name><surname>Leung</surname><given-names>HY</given-names></name></person-group>: <article-title>Mechanisms of FGFR-mediated carcinogenesis</article-title>. <source>Biochim Biophys Acta</source><volume>1823</volume>:<fpage>850</fpage>-<lpage>860</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22273505</pub-id></mixed-citation>
              </ref>
              <ref id="b8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guancial</surname><given-names>EA</given-names></name><name><surname>Werner</surname><given-names>L</given-names></name><name><surname>Bellmunt</surname><given-names>J</given-names></name><etal/></person-group>: <article-title>FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder</article-title>. <source>Cancer Med</source><volume>3</volume>:<fpage>835</fpage>-<lpage>844</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24846059</pub-id></mixed-citation>
              </ref>
              <ref id="b9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helsten</surname><given-names>T</given-names></name><name><surname>Elkin</surname><given-names>S</given-names></name><name><surname>Arthur</surname><given-names>E</given-names></name><etal/></person-group>: <article-title>The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing</article-title>. <source>Clin Cancer Res</source><volume>22</volume>:<fpage>259</fpage>-<lpage>267</lpage>, <year>2016</year><pub-id pub-id-type="pmid">26373574</pub-id></mixed-citation>
              </ref>
              <ref id="b10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>AG</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Al-Ahmadie</surname><given-names>H</given-names></name><etal/></person-group>: <article-title>Comprehensive molecular characterization of muscle-invasive bladder cancer</article-title>. <source>Cell</source><volume>171</volume>:<fpage>540</fpage>-<lpage>556.e25</lpage>, <year>2017</year><pub-id pub-id-type="pmid">28988769</pub-id></mixed-citation>
              </ref>
              <ref id="b11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>DC</given-names></name><name><surname>Baldo</surname><given-names>O</given-names></name><name><surname>Harnden</surname><given-names>P</given-names></name><etal/></person-group>: <article-title>FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer</article-title>. <source>J Pathol</source><volume>213</volume>:<fpage>91</fpage>-<lpage>98</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17668422</pub-id></mixed-citation>
              </ref>
              <ref id="b12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowles</surname><given-names>MA</given-names></name><name><surname>Hurst</surname><given-names>CD</given-names></name></person-group>: <article-title>Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity</article-title>. <source>Nat Rev Cancer</source><volume>15</volume>:<fpage>25</fpage>-<lpage>41</lpage>, <year>2015</year><pub-id pub-id-type="pmid">25533674</pub-id></mixed-citation>
              </ref>
              <ref id="b13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><etal/></person-group>: <article-title><italic toggle="yes">PIK3CA</italic> mutations frequently coexist with <italic toggle="yes">EGFR</italic>/<italic toggle="yes">KRAS</italic> mutations in non-small cell lung cancer and suggest poor prognosis in <italic toggle="yes">EGFR</italic>/<italic toggle="yes">KRAS</italic> wildtype subgroup</article-title>. <source>PLoS One</source><volume>9</volume>:<fpage>e88291</fpage>, <year>2014</year><pub-id pub-id-type="pmid">24533074</pub-id></mixed-citation>
              </ref>
              <ref id="b14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Roock</surname><given-names>W</given-names></name><name><surname>Claes</surname><given-names>B</given-names></name><name><surname>Bernasconi</surname><given-names>D</given-names></name><etal/></person-group>: <article-title>Effects of <italic toggle="yes">KRAS, BRAF, NRAS</italic>, and <italic toggle="yes">PIK3CA</italic> mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis</article-title>. <source>Lancet Oncol</source><volume>11</volume>:<fpage>753</fpage>-<lpage>762</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20619739</pub-id></mixed-citation>
              </ref>
              <ref id="b15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagano</surname><given-names>T</given-names></name><name><surname>Tachihara</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>Y</given-names></name></person-group>: <article-title>Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy</article-title>. <source>Cells</source><volume>7</volume>:<fpage>212</fpage>, <year>2018</year><pub-id pub-id-type="pmid">30445769</pub-id></mixed-citation>
              </ref>
              <ref id="b16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kompier</surname><given-names>LC</given-names></name><name><surname>Lurkin</surname><given-names>I</given-names></name><name><surname>van der Aa</surname><given-names>MN</given-names></name><etal/></person-group>: <article-title><italic toggle="yes">FGFR3, HRAS, KRAS, NRAS</italic> and <italic toggle="yes">PIK3CA</italic> mutations in bladder cancer and their potential as biomarkers for surveillance and therapy</article-title>. <source>PLoS One</source><volume>5</volume>:<fpage>e13821</fpage>, <year>2010</year><pub-id pub-id-type="pmid">21072204</pub-id></mixed-citation>
              </ref>
              <ref id="b17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuler</surname><given-names>M</given-names></name><name><surname>Cho</surname><given-names>BC</given-names></name><name><surname>Sayehli</surname><given-names>CM</given-names></name><etal/></person-group>: <article-title>Rogaratinib in patients with advanced cancers selected by <italic toggle="yes">FGFR</italic> mRNA expression: A phase 1 dose-escalation and dose-expansion study</article-title>. <source>Lancet Oncol</source><volume>20</volume>:<fpage>1454</fpage>-<lpage>1466</lpage>, <year>2019</year><pub-id pub-id-type="pmid">31405822</pub-id></mixed-citation>
              </ref>
              <ref id="b18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellmunt</surname><given-names>J</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Fougeray</surname><given-names>R</given-names></name><etal/></person-group>: <article-title>Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens</article-title>. <source>J Clin Oncol</source><volume>28</volume>:<fpage>1850</fpage>-<lpage>1855</lpage>, <year>2010</year><pub-id pub-id-type="pmid">20231682</pub-id></mixed-citation>
              </ref>
              <ref id="b19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>SK</given-names></name><name><surname>Rosenberg</surname><given-names>JE</given-names></name><name><surname>Hoffman-Censits</surname><given-names>JH</given-names></name><etal/></person-group>: <article-title>Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with <italic toggle="yes">FGFR3</italic> alterations</article-title>. <source>Cancer Discov</source><volume>8</volume>:<fpage>812</fpage>-<lpage>821</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29848605</pub-id></mixed-citation>
              </ref>
              <ref id="b20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Necchi</surname><given-names>A</given-names></name><name><surname>Pouessel</surname><given-names>D</given-names></name><name><surname>Leibowitz-Amit</surname><given-names>R</given-names></name><etal/></person-group>: <article-title>Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)</article-title>. <source>Ann Oncol</source><volume>29</volume>:<fpage>900P</fpage>, <year>2018</year> (<issue>suppl 8</issue>)</mixed-citation>
              </ref>
              <ref id="b21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hierro</surname><given-names>C</given-names></name><name><surname>Rodon</surname><given-names>J</given-names></name><name><surname>Tabernero</surname><given-names>J</given-names></name></person-group>: <article-title>Fibroblast growth factor (FGF) receptor/FGF inhibitors: Novel targets and strategies for optimization of response of solid tumors</article-title>. <source>Semin Oncol</source><volume>42</volume>:<fpage>801</fpage>-<lpage>819</lpage>, <year>2015</year><pub-id pub-id-type="pmid">26615127</pub-id></mixed-citation>
              </ref>
              <ref id="b22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chae</surname><given-names>YK</given-names></name><name><surname>Ranganath</surname><given-names>K</given-names></name><name><surname>Hammerman</surname><given-names>PS</given-names></name><etal/></person-group>: <article-title>Inhibition of the fibroblast growth factor receptor (FGFR) pathway: The current landscape and barriers to clinical application</article-title>. <source>Oncotarget</source><volume>8</volume>:<fpage>16052</fpage>-<lpage>16074</lpage>, <year>2017</year><pub-id pub-id-type="pmid">28030802</pub-id></mixed-citation>
              </ref>
              <ref id="b23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vento</surname><given-names>S</given-names></name><name><surname>Cainelli</surname><given-names>F</given-names></name><name><surname>Temesgen</surname><given-names>Z</given-names></name></person-group>: <article-title>Lung infections after cancer chemotherapy</article-title>. <source>Lancet Oncol</source><volume>9</volume>:<fpage>982</fpage>-<lpage>992</lpage>, <year>2008</year><pub-id pub-id-type="pmid">19071255</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
